Efficacy and Safety of Upadacitinib in Adults and Adolescents with Moderate-To-Severe Atopic Dermatitis: Subgroup Analysis of the Measure Up 1, Measure Up 2 and Ad Up Phase 3 Clinical Trials at 52 Weeks
AuthID
P-00Y-WVG
P-00Y-WVG